The Food and Drug Administration evaluates drugs for safety and efficacy, but now the Centers for Medicare and Medicaid Services wants to act as a political check on the FDA's decisions. Last week CMS refused to cover a novel Alzheimer's treatment for millions of patients because it disagreed with FDA approval.
